
Collegium Pharmaceutical (COLL) Stock Forecast & Price Target
Collegium Pharmaceutical (COLL) Analyst Ratings
Bulls say
Collegium Pharmaceutical is poised for long-term success due to its diversified portfolio of differentiated products in the high-demand areas of ADHD and pain management. The company's strategy of licensing and acquiring products has resulted in a strong pipeline and steady revenue growth. Although there are potential risks related to generic competition and reimbursement/pricing dynamics, Collegium has a solid financial foundation and is focused on expanding through strategic business development initiatives. Additionally, the company's 2026 guidance highlights the strength of its key product, Jornay PM, and the durability of its pain portfolio, providing confidence in its long-term outlook.
Bears say
Collegium Pharmaceutical is a diversified biopharmaceutical company facing significant competition from established products and generics, leading to potential payor reimbursement and access challenges. Additionally, the company is heavily reliant on third-party suppliers, which could result in disruptions or delays in product manufacturing. This could negatively impact the company's top-line growth and profitability. Despite expected growth in Jornay PM sales, the company's high operating cash flow margin may not be sustainable without continued capital deployment and business development opportunities.
This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Collegium Pharmaceutical (COLL) Analyst Forecast & Price Prediction
Start investing in Collegium Pharmaceutical (COLL)
Order type
Buy in
Order amount
Est. shares
0 shares